UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.765

Sortiert nach

Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients

Journal of viral hepatitis, 2015-11, Vol.22 (11), p.882-889

2015

Link zum Volltext

Verfügbarkeit prüfen

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom

Journal of affective disorders, 2017-08, Vol.218, p.291-298

2017

Link zum Volltext

Verfügbarkeit prüfen

Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens

Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (6), p.676-685

2014

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness and Long-Term Outcomes of Sovaldi (SOFOSBUVIR) for the Treatment of Chronic Hepatitis C Infected (HCV) Patients from a Swedish Societal Perspective

Value in health, 2014-11, Vol.17 (7), p.A675-A675

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis

Current medical research and opinion, 2012-11, Vol.28 (11), p.1841-1856

2012

Link zum Volltext

Verfügbarkeit prüfen

OP0114 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using A Matching-Adjusted Indirect Comparison

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.98-98

2016

Link zum Volltext

Verfügbarkeit prüfen

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.353-354

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Outcomes of Ledipasvir/Sofosbuvir (LDV/ SOF) for the Treatment of Chronic Hepatitis C Infected (HCV) Genotype 1 Patients in the UK

Value in health, 2014-11, Vol.17 (7), p.A675-A675

2014

Link zum Volltext

Verfügbarkeit prüfen

Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study

Journal of medical economics, 2013-05, Vol.16 (5), p.691-700

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Outcomes of Sofosbuvir (SOF) for the Treatment of Chronic Hepatitis C Infected (CHC) Patients

Value in health, 2013-11, Vol.16 (7), p.A357-A357

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of Using Either Multiplicative or Additive Utility Decrements in Decision Models

Value in health, 2013-11, Vol.16 (7), p.A579-A579

2013

Link zum Volltext

Verfügbarkeit prüfen

SAT0304 Long-Term Costs of Biologics in the Treatment of Psoriatic Arthritis in the United States

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A686-A686

2013

Link zum Volltext

Verfügbarkeit prüfen

Cost-Utility Analysis Of Sofosbuvir For Treatment Of Genotype2 Chronic Hepatitis C In Japan

Value in health, 2014-11, Vol.17 (7), p.A368-A368

2014

Link zum Volltext

Verfügbarkeit prüfen

Different Discounting Approaches and Their Impact in Economic Evaluation: A Practical Example Using Hepatitis B Vaccination

Value in health, 2013-11, Vol.16 (7), p.A355-A356

2013

Link zum Volltext

Verfügbarkeit prüfen

Economic Evaluation Of Sequencing Strategies In The Treatment Of Psoriatic Arthritis In The United States

Value in health, 2014-05, Vol.17 (3), p.A46-A46

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Costs Of Biologics In The Treatment Of Psoriatic Arthritis In The United States

Value in health, 2013-05, Vol.16 (3), p.A222-A222

2013

Link zum Volltext

Verfügbarkeit prüfen

1102 THE COST-EFFECTIVENESS OF TELAPREVIR (TVR) IN COMBINATION WITH PEGYLATED INTERFERON-ALFA AND RIBAVIRIN (PR) FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS

Journal of hepatology, 2012-04, Vol.56, p.S434-S434

2012

Link zum Volltext

Verfügbarkeit prüfen

A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options with Chronic Hepatitis C Virus Genotype 2 Infection

Value in health, 2013-11, Vol.16 (7), p.A341-A341

2013

Link zum Volltext

Verfügbarkeit prüfen

PIN7 The Comparative Efficacy of Telaprevir Versus Boceprevir in Treatment-Naive and Treatment-Experienced Patients with Genotype 1 Chronic Hepatitis

Value in health, 2011, Vol.14 (7), p.A266-A266

2011

Link zum Volltext

Verfügbarkeit prüfen

PIN4 Mixed-Treatment Comparison of the Efficacy and Safety of Antiretroviral Drugs Indicated for Treatment-Experienced HIV Patients

Value in health, 2012-11, Vol.15 (7), p.A385-A385

2012

Link zum Volltext

Verfügbarkeit prüfen

PIN56 Economic Value of Telaprevir for the Treatment of Previously Untreated F2 Fibrosis Chronic Hepatitis C Patients

Value in health, 2012-11, Vol.15 (7), p.A395-A395

2012

Link zum Volltext

Verfügbarkeit prüfen

High Therapeutic Efficiency With Sofosbuvir For The Treatment Of Chronic Hepatitis C

Value in health, 2014-11, Vol.17 (7), p.A371-A371

2014

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir For The Treatment Of Chronic Hepatitis C: A Comprehensive Cost-Effectiveness Analysis Across Hcv Genotypes, Pretreatment Conditions And Hiv Co-Infection

Value in health, 2014-11, Vol.17 (7), p.A366-A366

2014

Link zum Volltext

Verfügbarkeit prüfen

1088 IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN CHRONIC HEPATITIS C (CHC) PATIENTS

Journal of hepatology, 2010, Vol.52, p.S421-S421

2010

Link zum Volltext

Verfügbarkeit prüfen

9081 POSTER Network Meta-analysis of Second and Third-line Treatments on Overall Response and Overall Survival in Patients With Metastatic Non-small Cell Lung Cancer

European journal of cancer (1990), 2011, Vol.47, p.S616-S617

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.765

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.460)
Mit Volltextzugriff
(1.479)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom

Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens

Cost-Effectiveness and Long-Term Outcomes of Sovaldi (SOFOSBUVIR) for the Treatment of Chronic Hepatitis C Infected (HCV) Patients from a Swedish Societal Perspective

Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis

OP0114 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using A Matching-Adjusted Indirect Comparison

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

Long-Term Outcomes of Ledipasvir/Sofosbuvir (LDV/ SOF) for the Treatment of Chronic Hepatitis C Infected (HCV) Genotype 1 Patients in the UK

Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study

Long-Term Outcomes of Sofosbuvir (SOF) for the Treatment of Chronic Hepatitis C Infected (CHC) Patients

Impact of Using Either Multiplicative or Additive Utility Decrements in Decision Models

SAT0304 Long-Term Costs of Biologics in the Treatment of Psoriatic Arthritis in the United States

Cost-Utility Analysis Of Sofosbuvir For Treatment Of Genotype2 Chronic Hepatitis C In Japan

Different Discounting Approaches and Their Impact in Economic Evaluation: A Practical Example Using Hepatitis B Vaccination

Economic Evaluation Of Sequencing Strategies In The Treatment Of Psoriatic Arthritis In The United States

Long-Term Costs Of Biologics In The Treatment Of Psoriatic Arthritis In The United States

1102 THE COST-EFFECTIVENESS OF TELAPREVIR (TVR) IN COMBINATION WITH PEGYLATED INTERFERON-ALFA AND RIBAVIRIN (PR) FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS

A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options with Chronic Hepatitis C Virus Genotype 2 Infection

PIN7 The Comparative Efficacy of Telaprevir Versus Boceprevir in Treatment-Naive and Treatment-Experienced Patients with Genotype 1 Chronic Hepatitis

PIN4 Mixed-Treatment Comparison of the Efficacy and Safety of Antiretroviral Drugs Indicated for Treatment-Experienced HIV Patients

PIN56 Economic Value of Telaprevir for the Treatment of Previously Untreated F2 Fibrosis Chronic Hepatitis C Patients

High Therapeutic Efficiency With Sofosbuvir For The Treatment Of Chronic Hepatitis C

Sofosbuvir For The Treatment Of Chronic Hepatitis C: A Comprehensive Cost-Effectiveness Analysis Across Hcv Genotypes, Pretreatment Conditions And Hiv Co-Infection

1088 IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN CHRONIC HEPATITIS C (CHC) PATIENTS

9081 POSTER Network Meta-analysis of Second and Third-line Treatments on Overall Response and Overall Survival in Patients With Metastatic Non-small Cell Lung Cancer

Suchergebnisse filtern